Global Myocardial Infarction Drug Market Professional Survey Report 2019

Table of Contents

Executive Summary

1 Industry Overview of Myocardial Infarction Drug

• 1.1 Definition of Myocardial Infarction Drug
• 1.2 Myocardial Infarction Drug Segment by Type
  • 1.2.1 Global Myocardial Infarction Drug Production Growth Rate Comparison by Types (2014-2025)
  • 1.2.2 JVS-200
  • 1.2.3 KR-33028
  • 1.2.4 AMRS-001
  • 1.2.5 ANG-4011
  • 1.2.6 Balixafortide
  • 1.2.7 CAP-1002
  • 1.2.8 Cenderitide
  • 1.2.9 Others
• 1.3 Myocardial Infarction Drug Segment by Applications
  • 1.3.1 Global Myocardial Infarction Drug Consumption Comparison by Applications (2014-2025)
  • 1.3.2 Research Center
  • 1.3.3 Hospital
  • 1.3.4 Clinic
• 1.4 Global Myocardial Infarction Drug Overall Market
  • 1.4.1 Global Myocardial Infarction Drug Revenue (2014-2025)
  • 1.4.2 Global Myocardial Infarction Drug Production (2014-2025)
  • 1.4.3 North America Myocardial Infarction Drug Status and Prospect (2014-2025)
  • 1.4.4 Europe Myocardial Infarction Drug Status and Prospect (2014-2025)
  • 1.4.5 China Myocardial Infarction Drug Status and Prospect (2014-2025)
  • 1.4.6 Japan Myocardial Infarction Drug Status and Prospect (2014-2025)
  • 1.4.7 Southeast Asia Myocardial Infarction Drug Status and Prospect (2014-2025)
  • 1.4.8 India Myocardial Infarction Drug Status and Prospect (2014-2025)

2 Manufacturing Cost Structure Analysis

• 2.1 Raw Material and Suppliers
• 2.2 Manufacturing Cost Structure Analysis of Myocardial Infarction Drug
• 2.3 Manufacturing Process Analysis of Myocardial Infarction Drug
• 2.4 Industry Chain Structure of Myocardial Infarction Drug

3 Development and Manufacturing Plants Analysis of Myocardial Infarction Drug

• 3.1 Capacity and Commercial Production Date
• 3.2 Global Myocardial Infarction Drug Manufacturing Plants Distribution
• 3.3 Major Manufacturers Technology Source and Market Position of Myocardial Infarction Drug
• 3.4 Recent Development and Expansion Plans

4 Key Figures of Major Manufacturers

• 4.1 Myocardial Infarction Drug Production and Capacity Analysis
• 4.2 Myocardial Infarction Drug Revenue Analysis
• 4.3 Myocardial Infarction Drug Price Analysis
• 4.4 Market Concentration Degree

5 Myocardial Infarction Drug Regional Market Analysis

• 5.1 Myocardial Infarction Drug Production by Regions
  • 5.1.1 Global Myocardial Infarction Drug Production by Regions
  • 5.1.2 Global Myocardial Infarction Drug Revenue by Regions
• 5.2 Myocardial Infarction Drug Consumption by Regions
• 5.3 North America Myocardial Infarction Drug Market Analysis
  • 5.3.1 North America Myocardial Infarction Drug Production
  • 5.3.2 North America Myocardial Infarction Drug Revenue
  • 5.3.3 Key Manufacturers in North America
  • 5.3.4 North America Myocardial Infarction Drug Import and Export
• 5.4 Europe Myocardial Infarction Drug Market Analysis
  • 5.4.1 Europe Myocardial Infarction Drug Production
  • 5.4.2 Europe Myocardial Infarction Drug Revenue
  • 5.4.3 Key Manufacturers in Europe
  • 5.4.4 Europe Myocardial Infarction Drug Import and Export
• 5.5 China Myocardial Infarction Drug Market Analysis
  • 5.5.1 China Myocardial Infarction Drug Production
  • 5.5.2 China Myocardial Infarction Drug Revenue
  • 5.5.3 Key Manufacturers in China
  • 5.5.4 China Myocardial Infarction Drug Import and Export
• 5.6 Japan Myocardial Infarction Drug Market Analysis
  • 5.6.1 Japan Myocardial Infarction Drug Production
  • 5.6.2 Japan Myocardial Infarction Drug Revenue
  • 5.6.3 Key Manufacturers in Japan
  • 5.6.4 Japan Myocardial Infarction Drug Import and Export
• 5.7 Southeast Asia Myocardial Infarction Drug Market Analysis
  • 5.7.1 Southeast Asia Myocardial Infarction Drug Production
  • 5.7.2 Southeast Asia Myocardial Infarction Drug Revenue
  • 5.7.3 Key Manufacturers in Southeast Asia
  • 5.7.4 Southeast Asia Myocardial Infarction Drug Import and Export
• 5.8 India Myocardial Infarction Drug Market Analysis
  • 5.8.1 India Myocardial Infarction Drug Production
  • 5.8.2 India Myocardial Infarction Drug Revenue
  • 5.8.3 Key Manufacturers in India
  • 5.8.4 India Myocardial Infarction Drug Import and Export

6 Myocardial Infarction Drug Segment Market Analysis (by Type)

• 6.1 Global Myocardial Infarction Drug Production by Type
• 6.2 Global Myocardial Infarction Drug Revenue by Type
• 6.3 Myocardial Infarction Drug Price by Type

7 Myocardial Infarction Drug Segment Market Analysis (by Application)

• 7.1 Global Myocardial Infarction Drug Consumption by Application
• 7.2 Global Myocardial Infarction Drug Consumption Market Share by Application (2014-2019)

8 Myocardial Infarction Drug Major Manufacturers Analysis

• 8.1 BioCardia, Inc.
  • 8.1.1 BioCardia, Inc. Myocardial Infarction Drug Production Sites and Area Served
  • 8.1.2 BioCardia, Inc. Product Introduction, Application and Specification
  • 8.1.3 BioCardia, Inc. Myocardial Infarction Drug Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
  • 8.1.4 Main Business and Markets Served
• 8.2 Biscayne Pharmaceuticals, Inc.
  • 8.2.1 Biscayne Pharmaceuticals, Inc. Myocardial Infarction Drug Production Sites and Area Served
  • 8.2.2 Biscayne Pharmaceuticals, Inc. Product Introduction, Application and Specification
  • 8.2.3 Biscayne Pharmaceuticals, Inc. Myocardial Infarction Drug Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
  • 8.2.4 Main Business and Markets Served
• 8.3 Capricor Therapeutics, Inc.
  • 8.3.1 Capricor Therapeutics, Inc. Myocardial Infarction Drug Production Sites and Area Served
  • 8.3.2 Capricor Therapeutics, Inc. Product Introduction, Application and Specification
  • 8.3.3 Capricor Therapeutics, Inc. Myocardial Infarction Drug Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
  • 8.3.4 Main Business and Markets Served
• 8.4 CellProthera
  • 8.4.1 CellProthera Myocardial Infarction Drug Production Sites and Area Served
  • 8.4.2 CellProthera Product Introduction, Application and Specification
  • 8.4.3 CellProthera Myocardial Infarction Drug Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
  • 8.4.4 Main Business and Markets Served
• 8.5 Celyad SA
  • 8.5.1 Celyad SA Myocardial Infarction Drug Production Sites and Area Served
  • 8.5.2 Celyad SA Product Introduction, Application and Specification
  • 8.5.3 Celyad SA Myocardial Infarction Drug Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
  • 8.5.4 Main Business and Markets Served
• 8.6 Compugen Ltd.
  • 8.6.1 Compugen Ltd. Myocardial Infarction Drug Production Sites and Area Served
  • 8.6.2 Compugen Ltd. Product Introduction, Application and Specification
  • 8.6.3 Compugen Ltd. Myocardial Infarction Drug Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
  • 8.6.4 Main Business and Markets Served
• 8.7 CSL Limited
  • 8.7.1 CSL Limited Myocardial Infarction Drug Production Sites and Area Served
  • 8.7.2 CSL Limited Product Introduction, Application and Specification
  • 8.7.3 CSL Limited Myocardial Infarction Drug Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
  • 8.7.4 Main Business and Markets Served
• 8.8 Cynata Therapeutics Limited
  • 8.8.1 Cynata Therapeutics Limited Myocardial Infarction Drug Production Sites and Area Served
  • 8.8.2 Cynata Therapeutics Limited Product Introduction, Application and Specification
  • 8.8.3 Cynata Therapeutics Limited Myocardial Infarction Drug Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
  • 8.8.4 Main Business and Markets Served
• 8.9 FibroGen, Inc.
  • 8.9.1 FibroGen, Inc. Myocardial Infarction Drug Production Sites and Area Served
  • 8.9.2 FibroGen, Inc. Product Introduction, Application and Specification
  • 8.9.3 FibroGen, Inc. Myocardial Infarction Drug Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
  • 8.9.4 Main Business and Markets Served
• 8.10 Hemostemix Ltd
  • 8.10.1 Hemostemix Ltd Myocardial Infarction Drug Production Sites and Area Served
  • 8.10.2 Hemostemix Ltd Product Introduction, Application and Specification
  • 8.10.3 Hemostemix Ltd Myocardial Infarction Drug Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
  • 8.10.4 Main Business and Markets Served
• 8.11 Human Stem Cells Institute
• 8.12 HUYA Bioscience International, LLC
• 8.13 Immune Pharmaceuticals Inc.
• 8.14 Juventas Therapeutics, Inc.
• 8.15 Laboratoires Pierre Fabre SA
• 8.16 Lee's Pharmaceutical Holdings Limited
• 8.17 LegoChem Biosciences, Inc

9 Development Trend of Analysis of Myocardial Infarction Drug Market

• 9.1 Global Myocardial Infarction Drug Market Trend Analysis
  • 9.1.1 Global Myocardial Infarction Drug Market Size (Volume and Value) Forecast 2019-2025
• 9.2 Myocardial Infarction Drug Regional Market Trend
  • 9.2.1 North America Myocardial Infarction Drug Forecast 2019-2025
  • 9.2.2 Europe Myocardial Infarction Drug Forecast 2019-2025
  • 9.2.3 China Myocardial Infarction Drug Forecast 2019-2025
  • 9.2.4 Japan Myocardial Infarction Drug Forecast 2019-2025
  • 9.2.5 Southeast Asia Myocardial Infarction Drug Forecast 2019-2025
  • 9.2.6 India Myocardial Infarction Drug Forecast 2019-2025
• 9.3 Myocardial Infarction Drug Market Trend (Product Type)
• 9.4 Myocardial Infarction Drug Market Trend (Application)
• 10.1 Marketing Channel
  • 10.1.1 Direct Marketing
  • 10.1.2 Indirect Marketing
• 10.3 Myocardial Infarction Drug Customers

11 Market Dynamics

• 11.1 Market Trends
• 11.2 Opportunities
• 11.3 Market Drivers
• 11.4 Challenges
• 11.5 Influence Factors

12 Conclusion

13 Appendix

• 13.1 Methodology/Research Approach
  • 13.1.1 Research Programs/Design
  • 13.1.2 Market Size Estimation
  • 13.1.3 Market Breakdown and Data Triangulation
• 13.2 Data Source
  • 13.2.1 Secondary Sources
  • 13.2.2 Primary Sources
• 13.3 Author List